Dual Inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia
Luis A. Carvajal1, Daniela Ben Neriah1, Adrien Senecal2, Lumie Benard1, Victor Thiruthuvanathan1, Tatyana Yatsenko1, Swathi-Rao Narayanagari1,3, Justin C. Wheat1, Tihomira I. Todorova1, Kelly Mitchell1, Charles Kenworthy2, Vincent Guerlavais4, D. Allen Annis4, Boris Bartholdy1, Britta Will1,3,5,6, Jesus D. Anampa5, Ioannis Mantzaris5, Manuel Aivado4, Robert H. Singer2, Robert A. Coleman2, Amit Verma3,5,6 and Ulrich Steidl1,3,5,6,*
1Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
2Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
3Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
4Aileron Therapeutics, Cambridge, MA 02139, USA.
5Division of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
6Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
↵*Corresponding author. Email: ulrich.steidl@einstein.yu.edu
Hide authors and affiliations
Science Translational Medicine 11 Apr 2018:
Vol. 10, Issue 436, eaao3003
DOI: 10.1126/scitranslmed.aao3003
Abstract: http://stm.sciencemag.org/cgi/content/abstract/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed
Reprint: http://stm.sciencemag.org/cgi/rapidpdf/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed
Full Text: http://stm.sciencemag.org/cgi/content/full/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed